Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C. Andrade, Morgana M. Novaes, Jessica A. Pessoa, Sergio A. Mota-Rolim, Flávia L. Osório, Rafael Sanches, Rafael G. dos Santos, Luís Fernando Tófoli, Gabriela de Oliveira Silveira, Mauricio Yonamine7, Jordi Riba, Francisco R. Santos, Antonio A. Silva-Junior, João C. Alchieri10, Nicole L. Galvão-Coelho5,11, Bruno Lobão-Soares5,12, Jaime E. C. Hallak, Emerson Arcoverde, João P. Maia-de-Oliveira and Dráulio B. Araújo Psychological Medicine, June 2018, 1-9 https://www.cambridge.org/core doi.org/10.1017/S0033291718001356 Abstract Background. Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods. [...]
Lire la suite3rd International Medical Cannabis Conference (CannX 2018) Tel Aviv, Israël, October 14–16, 2018 Medical Cannabis and Cannabinoids, 2018, 1, 119–129 Published online : October 4, 2018 DOI: 10.1159/000493905 Abstracts CANNX18-0023 Co-Culture, Stigma and Deprivations among Medical Cannabis Patients in Israel H. Bonny-Noach Ariel University, Department of Criminology, Ariel, Israel CANNX18-0039 Cannabis Is Personal: The Intersection Between Human Genetics and Cannabis L. May, CEO & Founder of EndoCanna Health, Seattle, USA CANNX18-0046 Rationale to Evaluate Community-Led Interventions Employing Cannabis as Harm Reduction During the Opioid Overdose Crisis M.J. Milloy1, K. Heed2 1British Columbia Centre on Substance Use, Research, Vancouver, Canada; 2GrowX Global, Operations, Vancouver- BC, Canada CANNX18-0041 Concrete Evidence of Medical Cannabis Saving Lives and How Data Can Help [...]
Lire la suiteMedical Cannabis and Cannabinoids : An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? Magdalena Grill, Carina Hasenoehrl, Martin Storr, Rudolf Schicho Medical Cannabis and Cannabinoids, 2018, 1, 28–35 © 2018 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca DOI: 10.1159/000489036 Abstract : In the past few years, we have witnessed a surge of new reports dealing with the role of cannabinoids, synthetic as well as herbal, in the mechanisms of inflammation and carcinogenesis. However, despite the wealth of in vitro data and anecdotal reports, evidence that cannabinoids could act as beneficial drugs in inflammatory bowel disease (IBD) or in [...]
Lire la suiteCannabis – Phytochemical, Pharmacological and Clinical Evidence Scientific Symposium University of Vienna, Austria, November 15, 2018 Abstracts Organized by Herbal Medicinal Products Platform Austria (HMPPA) Society for Medicinal Plant and Natural Product Research (GA) Medical Cannabis and Cannabinoids, 2018, 1, 130–134 Published online: November 9, 2018 DOI: 10.1159/000494812 Breeding and Agronomical Techniques to Produce Medicinal Cannabis Gianpaolo Grassi CREA-CI, Research Centre for Cereal and Industrial Crops, Branch Station of Rovigo, Italy Cannabis Beyond the “Big Two” (THC and CBD)”: The Biological Potential of Minor Cannabinoids and of Non-Cannabinoid Constituents of Cannabis Giovanni Appendino1, Eduardo Muñoz2 1Dipartimento di Scienze del Farmaco, Largo Donegani 2, 28100 Novara, Italy; 2Maimonides Biomedical Research Institute of Córdoba. Avda Menendez Pidal s/n, 14004 Cordoba, [...]
Lire la suiteThe Effect of Light Spectrum on the Morphology and Cannabinoid Content of Cannabis sativa L. Gianmaria Magagnini, Gianpaolo Grassi, Stiina Kotiranta Medical Cannabis and Cannabinoids, 2018, 1, 19–27 DOI : 10.1159/000489030 Abstract Cannabis sativa L. flowers are the main source of Δ-9- tetrahydrocannabinol (THC) used in medicine. One of the most important growth factors in cannabis cultivation is light; light quality, light intensity, and photoperiod play a big role in a successful growth protocol. The aim of the present study was to examine the effect of 3 different light sources on morphology and cannabinoid production. Cannabis clones were grown under 3 different light spectra, namely [...]
Lire la suiteAcid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects Mitchell B. Liester Current Drug Abuse Reviews, 2014, 7, 146-156 1874-4745/14 $58.00+.00 © 2014 Bentham Science Publishers Abstract : Lysergic acid diethylamide (LSD) is a semisynthetic compound with strong psychoactive properties. Chemically related to serotonin, LSD was initially hypothesized to produce a psychosislike state. Later, LSD was reported to have benefits in the treatment of addictions. However, widespread indiscriminate use and reports of adverse affects resulted in the classification of LSD as an illicit drug with no accepted medical use. This article reviews LSD’s storied history from its discovery, to its use [...]
Lire la suiteExtractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067 Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and [...]
Lire la suiteCBD Gel Promising for Fragile X Syndrome Megan Brooks Medscape, 2019 https://www.medscape.com/viewarticle/913267?nlid=129947_2052&src=WNL_mdplsnews_190524_mscpedit_psyc&uac=292598PZ&spon=12&impID=1974025&faf=1 SAN FRANSICO — A clear transdermal cannabidiol (CBD) gel (ZYN002, Zynerba Pharmaceuticals) improved emotional and behavioral symptoms experienced by children and adolescents with fragile X syndrome in a phase 2 open-label study, the company reports. ZYN002 met its primary endpoint, with patients demonstrating a 46% improvement in the total score on the Anxiety, Depression, and Mood Scale (ADAMS) at week 12 compared to baseline. ZYN002 also led to meaningful improvements in all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), which addresses the key symptoms of fragile X syndrome, including social avoidance, [...]
Lire la suiteMedical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland Aleksi Mikael Markunpoika Hupli Medical Cannabis and Cannabinoids, 2018, 1, 112–118 DOI: 10.1159/000495307 https://www.karger.com/Article/FullText/495307 Abstract : This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse effects from prolonged use of this medication and afterwards other medications that were prescribed as alternatives, the patient discovered that cannabinoid therapeutics (CT) had been experimented inside the EU area to treat patients with [...]
Lire la suiteChemical and Biological Studies of Cannabis sativa Roots Mostafa A. Elhendawy, Amira S. Wanas, Mohamed M. Radwan, Nabil A. Azzaz, ElShahat S. Toson, Mahmoud A. ElSohly Medical Cannabis and Cannabinoids, 2018, 1, 104–111 DOI: 10.1159/000495582 https://www.karger.com/Article/FullText/495582 Abstract : The chemical study of Cannabis sativa roots led to the isolation and identification of 10 compounds. Their chemical structures were unambiguously established on the basis of 1D and 2D NMR spectroscopy and mass spectrometry as friedelan- 3-one (1), epifriedelanol (2), β-sitosterol (3), ergost-5- en-3-ol (4), methyl hexadecanoate (5), pentadecanoic acid (6), 10E-hexadecenoic acid (7), 4-hydroxy 3-methoxybenzaldehyde (8), β-sitosterol-β-D-glucoside (9) and p-coumaroyltyramine (10). Compounds 5–9 were reported for the [...]
Lire la suite